158 related articles for article (PubMed ID: 2411137)
41. CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125.
Canney PA; Wilkinson PM; James RD; Moore M
Br J Cancer; 1985 Jul; 52(1):131-3. PubMed ID: 2410004
[No Abstract] [Full Text] [Related]
42. Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas.
Masuho Y; Zalutsky M; Knapp RC; Bast RC
Cancer Res; 1984 Jul; 44(7):2813-9. PubMed ID: 6202400
[TBL] [Abstract][Full Text] [Related]
43. An initial appraisal of the value of serum carbohydrate antigenic determinant (CA 19-9) levels in patients with pancreatic cancer.
Buamah PK; Cornell C; Venables CW; Skillen AW
Eur J Cancer Clin Oncol; 1987 Jan; 23(1):87-91. PubMed ID: 2439345
[TBL] [Abstract][Full Text] [Related]
44. An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma.
Zurawski VR; Knapp RC; Einhorn N; Kenemans P; Mortel R; Ohmi K; Bast RC; Ritts RE; Malkasian G
Gynecol Oncol; 1988 May; 30(1):7-14. PubMed ID: 2452773
[TBL] [Abstract][Full Text] [Related]
45. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease.
Malkasian GD; Knapp RC; Lavin PT; Zurawski VR; Podratz KC; Stanhope CR; Mortel R; Berek JS; Bast RC; Ritts RE
Am J Obstet Gynecol; 1988 Aug; 159(2):341-6. PubMed ID: 2457318
[TBL] [Abstract][Full Text] [Related]
46. An improved radioimmunoassay for human ovarian tumor antigen NB/70K.
Knauf S; Taillon-Miller P
Gynecol Oncol; 1984 Sep; 19(1):67-73. PubMed ID: 6469090
[TBL] [Abstract][Full Text] [Related]
47. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
Suzuki H; Teshima K; Noda K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2719-23. PubMed ID: 6594978
[TBL] [Abstract][Full Text] [Related]
48. Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas.
Friedman EL; Hayes DF; Kufe DW
Cancer Res; 1986 Oct; 46(10):5189-94. PubMed ID: 3530435
[TBL] [Abstract][Full Text] [Related]
49. [CA 19-9 in early cancers of the bronchi. Comparison with the carcinoembryogenic antigen].
Vindimian M; Lafitte JJ; Wattre P
Biomed Pharmacother; 1987; 41(4):191-5. PubMed ID: 3476162
[TBL] [Abstract][Full Text] [Related]
50. [Serum levels and clinical evaluation of CA 19-9 in various diseases].
Toyama K; Noto M; Sakaguchi T; Adachi K; Mitomi H; Okada N; Ootaka H; Nakazawa H; Hara E
Gan No Rinsho; 1985 Mar; 31(3):293-8. PubMed ID: 2582158
[TBL] [Abstract][Full Text] [Related]
51. Detection of Ca antigen in sera from normal individuals and patients with benign and malignant breast disease.
Goodall AB; Evans CJ; Trivedi D; Coombes RC; Chantler SM
Br J Cancer; 1985 Aug; 52(2):177-82. PubMed ID: 2411281
[TBL] [Abstract][Full Text] [Related]
52. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas.
Klug TL; Bast RC; Niloff JM; Knapp RC; Zurawski VR
Cancer Res; 1984 Mar; 44(3):1048-53. PubMed ID: 6198078
[TBL] [Abstract][Full Text] [Related]
53. The role of cancer antigen 125 (CA 125) in the management of ovarian epithelial carcinomas.
Altaras MM; Goldberg GL; Levin W; Bloch B; Darge L; Smith JA
Gynecol Oncol; 1988 May; 30(1):26-34. PubMed ID: 2452770
[TBL] [Abstract][Full Text] [Related]
54. Serum levels of CA-125 in patients with endometriosis.
Giudice LC; Jacobs AJ; Bell CE; Lippmann L
Gynecol Oncol; 1986 Oct; 25(2):256-8. PubMed ID: 3463522
[No Abstract] [Full Text] [Related]
55. [Tumor-associated antigens and fibrin derivatives as reaction products of ovarian cancer].
Schröck R; Hafter R; Schmid L; Babic R; Ulm K; Gössner W; Graeff H
Geburtshilfe Frauenheilkd; 1986 Jan; 46(1):1-10. PubMed ID: 2420679
[TBL] [Abstract][Full Text] [Related]
56. [Significance of the serum levels of Ca 19-9 and CA 50 in gastric cancer].
Loizate Totorikaguena A; Lamiquiz Vallejo A; Domínguez Merru-Urrutia MJ
Rev Esp Enferm Apar Dig; 1987 Nov; 72(5 Pt 2):644-5. PubMed ID: 2452465
[No Abstract] [Full Text] [Related]
57. [Clinical usefulness of monoclonal antibody, CA 125 and CA 19-9 in ovarian cancer].
Saitoh S; Nakanishi A; Noda T; Ando Y; Katakami Y; Kiyozuka Y; Moriyama I; Ichijo M
Nihon Gan Chiryo Gakkai Shi; 1984 Dec; 19(10):2327-35. PubMed ID: 6598184
[No Abstract] [Full Text] [Related]
58. Preliminary results on the use of Ca 15-3 in malignant ovarian pathology.
Ferdeghini M; Gadducci A; Romagnoli S; Bartolini T; Facchini V; Scatena P; Bianchi R; Fioretti P
J Nucl Med Allied Sci; 1987; 31(4):299-302. PubMed ID: 3481812
[No Abstract] [Full Text] [Related]
59. CA 125 in gynecologic practice.
Malkasian GD; Podratz KC; Stanhope CR; Ritts RE; Zurawski VR
Am J Obstet Gynecol; 1986 Sep; 155(3):515-8. PubMed ID: 2428248
[TBL] [Abstract][Full Text] [Related]
60. [Clinical evaluation of a cancer antigen, CA 125, associated with ovarian cancer. I. Technical investigation and the reference value].
Sakurabayashi I; Kawai T; Suzuki M; Tamada T; Sato K; Yonezawa M
Rinsho Byori; 1984 Dec; 32(12):1345-9. PubMed ID: 6597875
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
